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Congenital heart defects are the most common birth defects. Major advances in open-heart surgery have led to rapidly evolving cohorts of adult
survivors and the majority of affected women now survive to childbearing age. The risk of cardiovascular complications during pregnancy and
peripartum depends on the type of the underlying defect, the extent and severity of residual haemodynamic lesions and comorbidities. Careful
individualized, multi-disciplinary pre-pregnancy risk assessment and counselling, including assessment of risks in the offspring and estimation on
long-term outcomes of the underlying heart defect, will enable informed decision making. Depending on the estimated risks, a careful follow-up
plan during pregnancy as well as a detailed plan for delivery and postpartum care can reduce the risks and should be made by the multi-
disciplinary team.
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Background and scope of the
problem
The field of pregnancy in women with heart disease is dynamic and
novel evidence is constantly evolving. The goal of this article is to
give an overview on how to incorporate this growing knowledge
into day-to-day practice regarding counselling, decision making,
and management of women with congenital heart disease before,
during, and after pregnancy.
Congenital heart defects (CHDs) affect 0.4–1.5% of the general
population.1 – 3 Nowadays due to improved surgical and medical
treatment, survival to adulthood has become the rule even for pa-
tients with the most complex lesions.4 This has resulted in a large
cohort of adult survivors, mostly still young and including many wo-
men in childbearing age.5,6 It is important to recognize that these pa-
tients are not cured and many are at high risk of cardiovascular
complications and increased risk of premature death.6
Pregnancy-related cardiac deaths have increased over the last
two decades.7 The proportion of pregnancy-related deaths attribu-
ted to CHD has, however, remained relatively low (see Figure 1).
This is in spite that in most clinics specialized in heart disease in preg-
nancy in developed countries; women with CHD comprise the lar-
gest group of patients.8,9 This may be partly explained by the fact
that most women with CHD are followed at specialized centres
and thus receive appropriate pre-conception assessment and coun-
selling, as well as structured follow-up during pregnancy. In contrast,
women with acquired heart disease sometimes present the first
time during pregnancy with a complication, such as myocardial in-
farction, arrhythmia, or aortic dissection. The prevalence of ischae-
mic heart disease complicating pregnancies is increasing, perhaps
related to trends in Western societies of having children later in
life and associated higher rates of cardiovascular risk factors in these
older women.7,10,11
Given the epidemiology of CHD with rapidly expanding cohorts
of young women with complex CHD (i.e. Fontan palliation for uni-
ventricular hearts), we have to prepare for an increasing number of
high-risk pregnancies.
Individual pregnancy risks:
enabling informed decision making
Haemodynamic changes during
pregnancy, delivery, and postpartum
Pregnancy and delivery require profound adaptations of the cardio-
vascular system to cope with the increased haemodynamic needs.
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The extent of these haemodynamic changes in healthy women is il-
lustrated in Figure 2.
Depending on the type and complexity of the congenital cardiac
defect and the severity of residual haemodynamic lesions, these nor-
mal adaptive responses of the cardiovascular system to the in-
creased demands of pregnancy, labour, and puerpurium can be
distorted in numerous ways.16 The occurrence of tachy-arrhythmias
or failure to adequately increase heart rate or cardiac output
(chronotropic incompetence, inadequate adaptation of pacemaker
programming, valve stenosis, rigid conduits, or baffles) during preg-
nancy and peripartum may further impair these adaptive mechan-
isms and precipitate decompensation.
The occurrence of obstetric complications, such as hypertensive
disorders of pregnancy, pre-eclampsia, or multiple pregnancies in-
crease the haemodynamic load of pregnancy and thus increase
the risk of maladaptation to haemodynamic needs and subsequently
increase the risk of cardiovascular complications in vulnerable pa-
tients.8,17–19 The increased risk of multiple pregnancies may be of
particular importance in women seeking assisted fertilization and
underscores the need for optimal multi-disciplinary pre-pregnancy
communication, counselling, and planning. Assisted reproductive
technologies carry in it risks that may endanger the pregnant woman
with cardiovascular disease, such as fluid retention and enhance-
ment of hypercoagulability.20
Risk assessment, counselling, and decision
making
Risk stratification in CHD is complicated by the diversity of lesions
and surgical repair techniques as well as by the variety of (residual)
haemodynamic lesions.
Guidelines recommend that all women with CHD should have
careful pre-pregnancy assessment and detailed pre-pregnancy coun-
selling prior to embarking on pregnancy. To fulfil this task, a compre-
hensive assessment by experienced cardiologists, obstetricians, and
specialists from other specialities is needed. Since most women with
CHD are followed at specialized centres, the opportunities for such
counselling are generally available. Nonetheless, studies show that in
reality counselling may be suboptimal.21–24
Figure 1 Number of maternal deaths related to cardiac disease
in the UK between 1985 and 2008, stratified for underlying heart
condition (modified from Cantwell et al.7).
Figure 2 Haemodynamic changes during pregnancy, peripartum, and postpartum. (A) Pregnancy (weeks of gestation). Modified from Robson
et al.12 (B) Peripartum. Modified from: Adams et al.13 BC, between contractions; Peak, at the peak of contraction; Stage 3, at the time of uterine
contraction. (C) Postportum. Modified from Robson et al.14,15 24 h pp, 24 h postpartum; 2w pp, 2 weeks postpartum. *For cohorts in (B) and (C),
relative changes from baseline were compared with the baseline values of the cohort from (A).
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Over the last few decades, there has been rapidly growing
evidence on pregnancy risks for a variety of CHD. One source of
evidence stems from lesion-specific studies. Most of these studies
are retrospective studies and often comprise relatively small num-
bers of pregnancies at risk and a wide variety of residual haemo-
dynamic lesions within specific groups of CHD. With the advent
of large multi-centre registries, such as the ROPAC registry, more
detailed data on lesion-specific outcomes will help better individual
risk stratification in the future. A meta-analysis summarizing the re-
sults of lesion-specific studies, published in 2007 by the ZAHARA
investigators, provides a useful estimation of the spectrum of risks
for a given CHD.25 All these studies are however flawed by the im-
portant biases of such small retrospective series and therefore must
be used carefully in individual decision making. Another source of
evidence stems from studies on larger numbers of women with
various forms of heart diseases and thus could define risk factors
for adverse outcomes based on patient history and residual haemo-
dynamic lesions and define risk scores.8,9,16 Based on these sources
of evidence and on collective clinical experience, expert panels have
defined risk-categories based on the underlying CHD, specific
haemodynamic residue as well as past medical history (see Figure 3
and corresponding Box 1). This so-called modified WHO classifica-
tion of maternal pregnancy risk has prospectively been validated
as the most reliable method of risk assessment.26 Though this is a
helpful tool for risk estimation, it should be emphasized that risk
stratification must be individualized (see Figure 3).
The assessment of risk for cardiovascular and foetal complica-
tions in women with CHD is a multi-disciplinary (see Figure 4) and
multi-step process, beginning with a detailed exploration of the
patient’s previous history, electrocardiogram, detailed echocardiog-
raphy and additional testing, such as exercise testing or advanced im-
aging, as appropriate. This process is outlined in Figure 3 and the
associated boxes. For individual decision making, it is very important
not only to estimate the probability of any adverse outcomes but to
distinguish between complications that can usually be well managed
(i.e. mild heart failure, atrial arrhythmias) and complications that may
be fatal or lead to permanent damage or deterioration (i.e. stroke,
irreversible deterioration of ventricular function).
An important aspect of risk stratification is to decide, whether a
pre-pregnancy intervention, be it medication or an invasive proced-
ure, may reduce the risk. This requires thought-out decision making
since sometimes the ‘cure is worse than the disease’. For example,
the risk of serious adverse cardiac events may be higher in women
with a mechanical aortic valve prosthesis compared with an
asymptomatic woman with severe aortic stenosis and normal
haemodynamic response to exercise. Furthermore, premature in-
terventions, such as prophylactic pulmonary valve replacement in
women with pulmonary regurgitation may expose the woman to
an uncertain long-term risk because of the life-time need for mul-
tiple subsequent interventions and higher risk of endocarditis, while
there is no proven evidence for risk reduction during pregnancy and
long term.36,37
Pre-pregnancy assessment must include a careful review of all
medications. Some cardiac medications, such as angiotensin-
converting-enzyme inhibitors, angiotensin- or aldosterone-antagonists,
are contraindicated during pregnancy. In women taking such medi-
cations, careful estimation of risk of being off such medications for a
certain time is mandatory. It may be wise to test the effect of cessa-
tion of such medications on ventricular function and well-being
prior to embark on pregnancy.
Foetal risk
In many women with congenital heart disease, the risk of miscarriage
is substantially increased. Foetal risks comprise mainly the risk of pre-
maturity, low birth weight/small for gestational age, offspring mortal-
ity, and the risk of recurrence of CHD. The risk of prematurity and
low birth weight/small for gestational age is closely related to the se-
verity of maternal heart disease and may be extremely high in women
with the most severe forms, such as univentricular physiology,
Eisenmenger-physiology, and unrepaired cyanotic defects. Prematur-
ity can result from spontaneous premature labour but also from
early-induced delivery for maternal (cardiac) reasons.25 Individual
risk factors that have been associated with adverse foetal outcomes
are listed in Box 2. However, risk scores developed from these risk
factors did not performwell in predicting foetal complications in a re-
cent prospective study.26 The association of complexity of maternal
heart disease and foetal outcome underscores the importance of
our multi-disciplinary efforts to maintain optimal maternal haemo-
dynamics and well-being during pregnancy. Foetal outcome is as-
sociated with uteroplacental blood flow. Recent evidence
suggests that uteroplacental blood flow is associated with mater-
nal haemodynamics in women with CHD. Impaired uteroplacental
Box 1 Factors associated with high maternal
risk8,18,22,25,27
Congenital heart defects/residual hemodynamic lesions with very
high maternal risk
(High risk of maternal mortality, consensus that pregnancy should be
discouraged)
† Severe symptomatic aortic valve stenosis
† Severe left atrio-ventricular valve stenosis
† Pulmonary arterial hypertension
† Systemic ventricular ejection fraction ,30%
† Poor functional class (NYHA III and IV)
† Marfan syndrome with ascending aortic diameter .45 mm
† Bicuspid aortic valve with ascending aortic diameter .50 mm
† Unrepaired severe coarctation
Congenital heart defects/residual haemodynamic lesions with
high maternal risk8,18,22,25,27
(High risk of morbidity or increased risk of maternal mortality,
consensus that very careful pre-pregnancy assessment and counselling
is required)
† Mechanical heart valve prosthesis
† Systemic right ventricle (transposition of the great arteries after
atrial switch operations or congenitally corrected transposition
of the great arteries)
† Fontan palliation for univentricular hearts
† Unrepaired or palliated cyanotic heart conditions
† Marfan syndrome with ascending aortic diameter ,40 mm
† Severe systemic atrio-ventricular valve regurgitation
† Asymptomatic left ventricular outflow tract stenosis with peak
gradient .50 mmHg or aortic valve area ,1.5 cm2
† Left atrio-ventricular valve stenosis with valve area opening
,2.0 cm2
† Systemic ventricular ejection fraction 30–40%
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blood flow may be the result of maternal impaired haemodynam-
ics, explaining partly the increased foetal complication rate in
women with CHD.38
The recurrence risk of isolated CHDs in the offspring is on aver-
age 3–5%.39 There is however substantial variability in recurrence
risk, depending on familial occurrence and type of defect.40,41 The
Figure 3 Multi-disciplinary, multi-step risk assessment, counselling, and management planning (Refs 6,8,18,22,25,27–34).
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recurrence risk is particularly high in left ventricular outflow tract
obstruction, including the hypoplastic left heart syndrome.42 Some
CHDs are associated with syndromes such as the 22q11 microdele-
tion syndrome (cono-truncal defects), Noonan syndrome (pulmon-
ary stenosis, atrial septal defects), and the Holt-Oram-syndrome
(atrial and ventricular septal defects). In these syndromes, inherit-
ance is autosomal dominant and recurrence risk is 50%. Genetic
testing using cord blood samples can be discussed with the affected
couple. In all patients with CHDs, including male patients, recur-
rence risk should be discussed and counselling by a geneticist should
be offered. Counselling by a geneticist may be particularly important
in patients asking for pre-implantation testing in the context of
assisted fertilization.
Effect of pregnancy on long-term
outcomes
Only few studies have assessed the impact of pregnancy on long-
term outcomes in women with heart disease. For women with
subaortic right ventricles in the setting of transposition of the
great arteries after atrial switch operations, there is a small but
definitive—and unpredictable—risk of irreversible deterioration of
systolic dysfunction of the subaortic systemic right ventricle.28,43,44
A case–control study in women with dilated cardiomyopathy and
systemic ventricular dysfunction suggests an increased short-term
risk of adverse cardiovascular events in women who went through
a pregnancy compared with matched controls without pregnancies.29
Similarly, women with aortic stenosis who went through pregnancy
have more events than non-pregnant controls.45 Several studies
have shown that women with CHD who have an adverse event dur-
ing pregnancy are more likely to experience adverse events after
pregnancy than women with uncomplicated pregnancies.46,47
A discussion about these uncertainties about the long-term effect
of pregnancy on outcomes of the underlying heart defect may thus
be offered to the women with CHD.
Prognosis of congenital heart condition
The prognosis of the woman with CHDmay interfere with her abil-
ity to raise children. This should be discussed when applicable, even
though34,48 such discussions are difficult as prognostication may be
uncertain and a number of barriers impair these discussions.48 The
discussion about pregnancy risks may however be a good setting to
explore the women’s wishes to discuss such issues. It is well known
that patient knowledge about long-term risks of the underlying
heart defects is often inappropriate.49 To detain discussions about
long-term prognosis of the underlying CHD may impede informed
decision making about family planning in affected women. It should
also be emphasized that it is important to offer these discussions not
only to our female patients but also to our male patients when they
contemplate to start a family!
Management planning
Once a woman has made a decision whether or not to accept the
risks of a pregnancy, it is important to plan future management. For
women not wishing to become pregnant, safe and effective contra-
ception should be provided.27,32 When there is no current but pos-
sible future pregnancy wish, the woman should be instructed to use
safe and effective contraception and when she desires to embark on
a pregnancy, to visit her cardiologist for an up-to-date assessment of
pregnancy risk (including echocardiography and exercise testing)
and construction of a pregnancy management plan before discon-
tinuing her contraceptive.
For women, who wish to become pregnant it is important to
clearly define management during pregnancy and to provide obstet-
ric assessment to ascertain up-to-date vaccination and initiation of
appropriate prophylactic measures, such as folic acid supplementa-
tion as well as recommendations for smoking cessation and abstin-
ence from alcohol.
Management of pregnancy in
women with congenital heart
disease
General aspects
For each pregnancy, a clear follow-up planmust be provided. The con-
tent of this plan is dependant on the estimatedmaternal and foetal risk.
While high-risk pregnancies (see Figure 3, Box 1) must bemanaged by a
dedicated, experienced multi-disciplinary team at a tertiary care cen-
tre, women at low risk for cardiovascular and foetal complications can
often be managed at regional centres. Good collaboration between
regional centres and tertiary referral centres is of paramount import-
ance. All pregnant women with CHD should be offered foetal echo-
cardiography between 18 and 21 weeks of gestation.
The frequency of cardiologic follow-up visits during pregnancy
must be individualized according to estimated risks and anticipated
complications based on the comprehensive risk assessment (see
Figure 3). For women with low or intermediate risk, assessment
towards the end of the first trimester, 20 weeks of gestation
and at peak of haemodynamic load at 28–32 weeks of gestation
is appropriate. Those at high risk needmonthly or bimonthly follow-
up.22 Dependent on individual risk stratification and the course
during pregnancy, follow-up may however significantly differ from
this scheme. The importance of patient education cannot be over-
emphasized. Every woman, who experiences novel or worsening
symptoms during pregnancy (i.e. palpitations or increasing shortness
of breath) should be encouraged to seek prompt assessment by her
specialized multi-disciplinary team.
The woman who had not had
pre-conception assessment and
counselling
Occasionally, women present first to a specialist multi-disciplinary
centre when already pregnant. In these patients, assessment and
risk stratification follows generally the same multi-disciplinary, step-
wise approach as pre-conception counselling and assessment, al-
though with certain variations.
Basis of the assessment is a comprehensive evaluation of the
patient’s history, a thorough physical examination, an electrocardio-
gram, and a detailed echocardiography. However, as a comprehen-
sive assessment of maternal health is of paramount importance
for the estimation of maternal and foetal risk of adverse events,
additional testing may be required.
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Submaximal exercise testing to evaluate exercise capacity, heart
rate, and blood pressure response to exercise and exercise-induced
arrhythmias can be safely performed during pregnancy.22 Given the
high chance of spontaneousmiscarriage before 12weeks, it may how-
ever be prudent to avoid exercise testing in the first trimester, if pos-
sible, as any temporal relationship between miscarriage and exercise
testingmay bemisconstrued as causal rather than pure chance.When
an exercise test is performed, the aim is to achieve 80% of the pre-
dicted heart rate. As chronotropic incompetence is common in adults
with CHD, cardio-pulmonary exercise testing with measuring
gas-exchange, aiming for a respiratory exchange ratio of 1.0 may be
an alternative to standard bicycle or treadmill exercise testing.
The use of cardiac magnetic resonance imaging is regarded safe,
particularly after the first trimester, but the use of gadolinium-
contrast should be avoided. This may be particularly indicated for
imaging of the entire aorta in women with Marfan syndrome or
other aortic diseases. Methods using ionizing radiation (radiography,
computed tomography, or scintigraphy) are generally avoided,
unless they provide critical information that cannot be obtained
with other methods.22
If the assessment reveals a very high-risk condition (see Figure 3,
Box 1), termination of pregnancy should be discussed, preferably
early in pregnancy. However, termination of pregnancy carries risks
and for women with high-risk lesions this should be performed in a
tertiary centre.
Need for intervention or cardiac surgery
during pregnancy
Although percutaneous interventions are generally possible during
pregnancy, the decision to perform such an intervention requires
careful interdisciplinary assessment with weighing risks and benefits.
Procedures should be performed by experienced teams at tertiary
care centres only, with an aim to keep the radiation dose to the foe-
tus as minimal as possible by shortening radiation time, using bra-
chial artery access and shielding of the uterus. If possible, the
intervention should be performed in the second trimester after
completion of organogenesis but before the uterus has become
very large. The timing of interventions remains debateable, how-
ever. Open-heart surgery on cardio-pulmonary bypass carries a
high risk of foetal loss. If cardiac surgery can be delayed until the
28th week of gestation, prior delivery after lung maturity induction
should be considered.22
Occurrence and management of heart
failure in pregnancy and peripartum
A recent multi-centre study has shown two peaks for the occur-
rence of heart failure in women with heart disease.50 One peak
was towards the end of the second trimester of pregnancy, when
Box 2 Risk of neonatal events8,18,35
Maternal pre-pregnancy functional class .II or cyanosis
Maternal left heart obstruction
Smoking during pregnancy
Multiple gestation
Use of oral anti-coagulants during pregnancy
Mechanical heart valve prosthesis
Figure 4 Multi-disciplinary team. CHD, congenital heart disease; EP, electrophysiology; ICU, intensive care unit; PHT, pulmonary hypertension.
Additional teams and services may need to be involved (i.e. social service) as per individual needs of the pregnant woman. In some services, ma-
ternal foetal medicine specialists are part of the team.
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the cardiovascular demands reach their plateau and the second peak
was peri- and early postpartum. It is however important to empha-
size that the manifestation of heart failure may differ between differ-
ent types of CHD as well as between individuals.
Towards later stages of pregnancy diagnosis of heart failure
may be difficult as its signs and symptoms (shortness of breath
on exertion, peripheral oedema, and sinus tachycardia) may be
difficult to distinguish from normal findings in late pregnancy.
Clinical judgment of fluid status is important and must be supple-
mented by regular laboratory and echocardiographic assess-
ments. A chest X-ray is relatively harmless for the foetus and
can be performed when required. Serial measurements of natri-
uretic peptides (Pro-BNP or BNP) may help in risk stratifica-
tion.30,33 Normal levels of natriuretic peptides at 20 weeks of
pregnancy seem to provide a good negative predictive value
regarding the occurrence of cardiovascular complications. Al-
though elevated or rising levels of natriuretic peptides do not ne-
cessarily predict cardiovascular complications, it may be prudent
to follow these women closely.
If overt heart failure occurs during pregnancy, patients should be
admitted to a tertiary care centre. Precipitating factors, such as
(intermittent) arrhythmia, should be actively sought and excluded.
Bed rest, supplemental oxygen, and careful fluid balance with daily
weight measurements should be initiated. Inotropes may be needed
to improve heart failure and careful administration of diuretics
may be used to improve pulmonary congestion but overdiuresis
with worsening uteroplacental blood flow must be avoided.51
Apart from b-blockers, standard heart failure treatment such
as angiotensin-converting-enzyme inhibitors or aldosterone-
antagonists is contraindicated in pregnancy. Hydralazine and ni-
trates may be used for afterload reduction.22 After delivery, the
use of angiotensin-converting-enzyme inhibitors is usually safe
for the baby in breast-feeding women. A detailed list regarding re-
commendations for drug use during pregnancy and lactation can be
found within the ESC guidelines.22 Good thromboembolic
prophylaxis is mandatory, particularly in patients with bed rest.
In the case of refractory heart failure delivery should be contem-
plated as soon as the foetus is viable, or, in the case of persistent
haemodynamic instability, irrespective of the duration of gestation,
as maternal health always has priority. Lung maturity induction
with corticosteroids may lead to fluid retention and worsening
of heart failure. After restoration of haemodynamic stability post-
partum, afterload reduction with angiotensin-converting-enzyme
inhibitors should be started.
In women with cardiac pacemakers and implanted cardiac defi-
brillators it is important to document the current programming of
the device (i.e. the heart rate, when anti-tachycardia pacing or defib-
rillation will be administered). In the case of any uncertainties, it is
advisable to consult the patient’s cardiologist and/or electrophysi-
ologist in order to discuss the need for modifications of pacemaker
or defibrillator programming.
Women with mechanical heart valves
Women with mechanical heart valves are at high risk of thrombo-
embolic events.52 – 54 Several strategies of anti-coagulation have
been reported.53,55,56Anti-coagulation with vitamin K antagonists
throughout pregnancy is safest for the mother and provides the low-
est risk for valve thrombosis.22,53 Offspring of women requiring low
doses of vitamin K antagonists (,5 mg Warfarin or ,3 mg phen-
procoumon) tomaintain therapeutic international normalized ratios
have a low risk of embryopathy and foetal loss compared with those
requiring higher doses.52,57–61 Continuation of the vitamin K antag-
onist throughout pregnancy should be considered in these wo-
men.22 Heparins are associated with more valve thrombosis but
do not cross the placenta and thus do not carry the risk of embryo-
pathy. Subplacental bleeding with the risk of pregnancy loss is asso-
ciated with all anti-coagulation regimens.52 – 54,58 Importantly,
anti-coagulation with low-molecular-weight heparin without me-
ticulous monitoring of anti-factor Xa levels is inappropriate and
dangerous.62 All pregnant women with mechanical heart valves
need to be closely followed by a multi-disciplinary team at a tertiary
care centre with a high-risk pregnancy program.22 A detailed man-
agement plan regarding the anti-coagulation regimen during delivery
and peripartum is particularly important.
Arrhythmias
Arrhythmias are by far the most common complication in adults
with CHD and complicate a substantial number of pregnan-
cies.8,9,18,63,64 The most common type of arrhythmia is atypical atrial
flutter (intra-atrial re-entrant tachycardia) caused by atrial scars.
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Table 1 Obstetric drugs, their cardiovascular side effects and precautions in women with congenital heart disease
Cardiovascular side effects Contraindications and precautions
Drugs to treat premature contractions
b-Mimetics (i.e. hexoprenaline) Tachycardia, arrhythmias Obstruction of left-sided atrio-ventricular valve
Propensity for arrhythmias
Atosiban (oxytocin antagonist) None None
Drugs for induction of labour
Misoprostol Coronary vasospasm, arrhythmias
Oxytocin Systemic hypotension Only low-dose continuous infusion or small repeated bolus
Drugs to control postpartum bleeding
Oxytocin Systemic hypotension Only low-dose continuous infusion or small repeated bolus
Prostaglandin F analogues Increase in pulmonary pressures Pulmonary hypertension, right ventricular failure
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Arrhythmias increase the risk of thromboembolic complications
and are an important trigger for the occurrence of heart failure.
Women with new-onset palpitations or sudden worsening of short-
ness of breath thus require prompt assessment by the multi-
disciplinary team. Most women with sustained or severely symp-
tomatic arrhythmias during pregnancy need to be admitted. De-
pending on the underlying cardiac condition and haemodynamic
stability a rate- or rhythm control strategy must be chosen, although
rhythm control is often preferred over rate control in pregnant wo-
men with CHD and new-onset arrhythmias. Regarding anti-
arrhythmic drug treatment, b-blockers are first choice for most ar-
rhythmias. A detailed list regarding recommendations for drug use
during pregnancy and lactation can be found within the ESC guide-
lines.22 Careful assessment for the need for anti-coagulation is
mandatory.
Obstetric complications and their impact
on cardiac disease
Pre-eclampsia and multiple pregnancies may be important modifiers
of the risk of cardiovascular complications in women with CHD. In
the ROPAC registry (a prospective multi-centre, multi-national
registry led by the European Society of Cardiology), women with
structural heart disease who developed pre-eclampsia had a 30%
risk of heart failure.50 Women at risk for pre-eclampsia should be
Box 4 Requirements for a comprehensive multi-disciplinary delivery plan
1. Information on the underlying heart defect and current haemodynamics
Exact cardiac diagnosis, previous surgical, and interventional procedures
In the case of complex cardiac or venous anatomy, a picture of the woman’s heart is advisable
Previous cardiovascular complications
Current cardiovascular findings and important residual lesions
2. Specific recommendations and pitfalls
Use of air bubble filters (see Figure 5) in women with risk of paradoxical embolism
Site of blood pressure measurements in women with occlusion of arm arteries (i.e. after subclavian flap repair for coarctation of the aorta or previous
classical Blalock-Taussig-Shunts)
3. Anticipated complications
Type and expected timing of the occurrence (i.e. pulmonary oedema in Stage 3 of delivery in women with left-sided atrio-ventricular valve
obstruction)
Suggested management in the case of complications (i.e. arrhythmias, heart failure)
Contact details of involved cardiologists in case of complications
List of specific drugs that need to be immediately available on the labour ward. In the case of drugs that are not commonly used on the labour ward (i.e.
amiodarone) clear instructions on how to prepare and use such drugs is mandatory.
4. Caution about obstetric drugs if adverse effects are expected (see Table 1)
b-Mimetics (i.e. hexoprenaline): A no restriction A caution A do not use
Atosiban (oxytocin antagonist): A no restriction A caution A do not use
Misoprostol: A no restriction A caution A do not use
Oxytocin: A no restriction A caution A do not use
Prostaglandin F analogues: A no restriction A caution A do not use
5. Detailed list of medications
6. Allergies
7. Information on important obstetric issues
Previous obstetric history and complications
Estimated date of delivery
8. Recommendation for delivery
Mode and timing of delivery (i.e. spontaneous delivery or induction at pre-specified date)
Recommendation for anaesthesia during delivery
Recommendation for rhythm monitoring during labour and delivery
Recommendation for type and duration of haemodynamic monitoring during labour and delivery
9. Detailed plan for postpartum care
Place of postpartum care (intensive care unit, cardiology ward, and obstetric ward)
Necessity and duration of rhythm monitoring postpartum
If required, recommendation for type and duration of haemodynamic monitoring postpartum
Recommendation for duration of postpartum stay in hospital (24 h/48 h/72 h)
Specific precautions and treatment recommendations (i.e. careful fluid balance)
Recommendation for investigations postpartum (i.e. pre-discharge echocardiography)
10. Follow-up plan after discharge from hospital
Box 3 Conditions in which caesarean section is
preferred over vaginal delivery
Women with an ascending aorta diameter .45 mm
Pre-term labour while on oral anti-coagulation
Women with severe aortic stenosis experiencing symptoms during
pregnancy (preferably general anaesthesia and endotracheal
intubation)
Severe heart failure
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offered prophylactic administration of low-dose aspirin after the
12th week of gestation.
Some commonly used drugs for management of obstetric compli-
cations may have adverse effects on the cardiovascular system. Ob-
stetric drugs, their potential cardiovascular side effects, and cautions
in their use in women with CHD are listed in Table 1.
Multi-disciplinary delivery plan
Haemodynamic changes during delivery and early postpartum in
healthy women are depicted in Figure 2. The type of CHD and re-
sidual haemodynamic lesions may affect the ability of the cardiovas-
cular system to respond to these demands. Effective analgesia and
assisted second stage of delivery can effectively decrease the add-
itional haemodynamic load of labour. Assisted delivery may how-
ever be associated with a higher risk of postpartum haemorrhage
and high-degree lacerations.65 The average blood loss during vaginal
delivery of 500 mL counteracts the impact of auto-transfusion from
the contracting uterus at stage 3 of delivery. Blood loss with caesar-
ean section is usually higher (on average 1000 mL). The impact of
anaesthesia and anaesthetic drugs on cardiovascular function in wo-
men with CHD is beyond the scope of this article but underscores
the need for a multi-disciplinary team, including experienced anaes-
thetists, familiar with special haemodynamic aspects of CHD. With
very few exemptions listed in Box 3, vaginal delivery, often with early
epidural analgesia is the preferred mode of delivery in women with
CHD.
A multi-disciplinary delivery plan, based on local experience, lo-
gistics, and infrastructure (i.e. possibilities for monitoring on labour
ward) should be provided in all women with CHD well before the
estimated delivery date. It must be ascertained that this delivery plan
is available and accessible at all times and by all team members in-
volved in the care of the woman with CHD. Antibiotic prophylaxis
against infective endocarditis is no longer recommended for vaginal
delivery. A checklist for important information that must be covered
in the delivery plan is outlined in Box 4.
Conflict of interest: none declared.
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